GlaxoSmithKline has predicted a return to growth in China next year as it slowly begins to repair the damage from a corruption scandal which shattered the company’s reputation in one of the world’s most important pharmaceuticals markets.
葛兰素史克(GSK)预计，明年其在华业务将恢复增长。该公司正慢慢着手修复一桩腐败丑闻造成的损害，那桩丑闻令该公司在manbetx app苹果 最重要的制药市场之一声誉扫地。
您已阅读14%（311字），剩余86%（1856字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。